Literature DB >> 7498309

Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist.

N Eshhar1, S Striem, R Kohen, O Tirosh, A Biegon.   

Abstract

This study examines the ability of (+)-(3S,4S)-7-hydroxy-delta 6-tetrahydrocannabinol-1,1-dimethylheptyl (HU-211), a non-competitive NMDA receptor antagonist to: (1) rescue neurons in culture from injury evoked by sodium nitroprusside, hydrogen peroxide (H2O2) and oxygen glucose deprivation; and (2) scavenge reactive oxygen species in vitro. Qualitative and quantitative assessments of cell survival have indicated that: (1) Neuronal cell injury produced following deprivation of oxygen and glucose was significantly attenuated by 5 microM HU-211. (2) Glial and neuronal cell damage induced by sodium nitroprusside was markedly ameliorated by 10 microM HU-211. (3) HU-211 reduced protein oxidation initiated by gamma irradiation, and scavenged peroxyl radicals. (4) HU-211 carries an oxidation potential of 550 mV. These findings suggest that HU-211 holds a unique position among putative neuroprotectant agents in that it combines NMDA receptor antagonistic activity and free radical scavenging abilities in a single molecule.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498309     DOI: 10.1016/0014-2999(95)00271-l

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

Review 1.  Potential role of cannabinoids in Parkinson's disease.

Authors:  J Sevcík; K Masek
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

2.  Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility.

Authors:  E Pop; F Soti; M E Brewster; Y Barenholz; V Korablyov; R Mechoulam; V Nadler; A Biegon
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

Review 4.  Cannabinoids and neuroprotection in basal ganglia disorders.

Authors:  Onintza Sagredo; Moisés García-Arencibia; Eva de Lago; Simone Finetti; Alessandra Decio; Javier Fernández-Ruiz
Journal:  Mol Neurobiol       Date:  2007-06-23       Impact factor: 5.590

Review 5.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 7.  Prospects for cannabinoid therapies in basal ganglia disorders.

Authors:  Javier Fernández-Ruiz; Miguel Moreno-Martet; Carmen Rodríguez-Cueto; Cristina Palomo-Garo; María Gómez-Cañas; Sara Valdeolivas; Carmen Guaza; Julián Romero; Manuel Guzmán; Raphael Mechoulam; José A Ramos
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 8.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

9.  The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia.

Authors:  Ramazan Durmaz; Hilmi Ozden; Güngör Kanbak; Erinç Aral; Okan Can Arslan; Kazim Kartkaya; Kubilay Uzuner
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

10.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.